Nucleic Acids Research, Vol 27, Issue 13 2569-2577, Copyright © 1999 by Oxford University Press
TJ Parry, C Cushman, AM Gallegos, AB Agrawal, M Richardson, LE Andrews, L Maloney, VR Mokler, FE Wincott and PA Pavco
Vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR
play important roles in physiological and pathological angiogenesis.
Ribozymes that target the VEGF receptor mRNAs were developed and their
biological activities in cell culture and an animal model were assessed.
Ribozymes targeting Flt-1 or KDR mRNA sites reduced VEGF-induced
proliferation of cultured human vascular endothelial cells and specifically
lowered the level of Flt-1 or KDR mRNA present in the cells. Anti- Flt-1
and KDR ribozymes also exhibited anti-angiogenic activity in a rat corneal
pocket assay of VEGF-induced angiogenesis. This report illustrates the
anti-angiogenic potential of these ribozymes as well as their value in
studying VEGF receptor function in normal and pathophysiologic states.
ARTICLES
Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA
Ribozyme Pharmaceuticals, Inc., 2950 Wilderness Place, Boulder, CO 80301, USA and.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J Heidemann, D G Binion, W Domschke, and T Kucharzik Antiangiogenic therapy in human gastrointestinal malignancies. Gut, October 1, 2006; 55(10): 1497 - 1511. [Full Text] [PDF]
|
|
|
|
 |
|
 D.-G. Bae, T.-D. Kim, G. Li, W.-H. Yoon, and C.-B. Chae Anti-Flt1 Peptide, a Vascular Endothelial Growth Factor Receptor 1-Specific Hexapeptide, Inhibits Tumor Growth and Metastasis Clin. Cancer Res., April 1, 2005; 11(7): 2651 - 2661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Zhang, C. R. Dass, E. Sumithran, N. Di Girolamo, L.-Q. Sun, and L. M. Khachigian Effect of Deoxyribozymes Targeting c-Jun on Solid Tumor Growth and Angiogenesis in Rodents J Natl Cancer Inst, May 5, 2004; 96(9): 683 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ruggeri, J. Singh, D. Gingrich, T. Angeles, M. Albom, H. Chang, C. Robinson, K. Hunter, P. Dobrzanski, S. Jones-Bolin, et al. CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models Cancer Res., September 15, 2003; 63(18): 5978 - 5991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stopeck, M. Sheldon, M. Vahedian, G. Cropp, R. Gosalia, and A. Hannah Results of a Phase I Dose-escalating Study of the Antiangiogenic Agent, SU5416, in Patients with Advanced Malignancies Clin. Cancer Res., September 1, 2002; 8(9): 2798 - 2805. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yang, X. Xin, C. Zlot, G. Ingle, G. Fuh, B. Li, B. Moffat, A. M. de Vos, and M. E. Gerritsen Vascular Endothelial Cell Growth Factor-Driven Endothelial Tube Formation Is Mediated by Vascular Endothelial Cell Growth Factor Receptor-2, a Kinase Insert Domain-Containing Receptor Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 1934 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Bramlage, E. Luzi, and F. Eckstein HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture Nucleic Acids Res., November 1, 2000; 28(21): 4059 - 4067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Amarzguioui, G. Brede, E. Babaie, M. Grotli, B. Sproat, and H. Prydz Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes Nucleic Acids Res., November 1, 2000; 28(21): 4113 - 4124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Jarvis, K. S. Bouhana, M. E. Lesch, S. A. Brown, T. J. Parry, D. J. Schrier, S. W. Hunt III, P. A. Pavco, and C. M. Flory Ribozymes as Tools for Therapeutic Target Validation in Arthritis J. Immunol., July 1, 2000; 165(1): 493 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Pavco, K. S. Bouhana, A. M. Gallegos, A. Agrawal, K. S. Blanchard, S. L. Grimm, K. L. Jensen, L. E. Andrews, F. E. Wincott, P. A. Pitot, et al. Antitumor and Antimetastatic Activity of Ribozymes Targeting the Messenger RNA of Vascular Endothelial Growth Factor Receptors Clin. Cancer Res., May 1, 2000; 6(5): 2094 - 2103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. McMahon VEGF Receptor Signaling in Tumor Angiogenesis Oncologist, April 1, 2000; 5(90001): 3 - 10. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Li, G. Fuh, G. Meng, X. Xin, M. E. Gerritsen, B. Cunningham, and A. M. de Vos Receptor-selective Variants of Human Vascular Endothelial Growth Factor. GENERATION AND CHARACTERIZATION J. Biol. Chem., September 15, 2000; 275(38): 29823 - 29828. [Abstract] [Full Text] [PDF]
|
|